A recombinant collagen composition having improved pigmentation and scar formation reduction effects and a preparation method thereof

Abstract

This invention provides a recombinant collagen composition and its preparation method that have the effects of improving pigmentation and reducing scar formation. The composition comprises, by weight percentage, 1%~10% organosilicon, 0.1%~5% recombinant collagen, 3%~15% glycerol, 0.1%~1.5% carbomer, 0.2%~2% 1,2-hexanediol, 0.1%~1% p-hydroxyacetophenone, 0.05%~1% polyoxyethylene hydrogenated castor oil, and water, with a pH value of 5.5~7.0. The organosilicon is a mixture of polydimethylsiloxane, cyclopentamethylsiloxane, fumed silica, and polydimethylsiloxane crosslinked polymer in a weight ratio of 1:(0.3~0.8):(0.05~0.3):(0.1~0.5). This invention achieves a synergistic effect by combining the physical barrier function of organosilicon with the biological repair function of recombinant collagen, thereby simultaneously improving pigmentation and reducing scar formation. The system is stable, has a refreshing feel, and is gentle and non-irritating, making it widely applicable in scar repair, acne scar care, and post-medical aesthetic repair.

Description

Technical Field

[0001] This invention relates to the field of cosmetics and topical skin care preparations, and in particular to a recombinant collagen composition and its preparation method that has the effect of improving pigmentation and reducing scar formation. Background Technology

[0002] Hyperpigmentation is a common pigmentary disorder in dermatology, mainly including post-inflammatory hyperpigmentation (PIH). Post- inflammatory Hyperpigmentation Post-inflammatory hyperpigmentation (PIH) includes melasma, freckles, and age spots. Among them, post-inflammatory hyperpigmentation is secondary to skin inflammatory reactions such as acne, trauma, post-laser treatment, and chemical peels. Its pathogenesis involves the activation of melanocytes by inflammatory mediators (such as prostaglandin E2, leukotrienes, IL-1α, etc.), leading to upregulation of tyrosinase activity and increased melanin synthesis, accompanied by impaired skin barrier function and abnormal melanin distribution in keratinocytes.

[0003] Scar formation is an abnormal repair outcome following damage to the dermis. When fibroblasts proliferate excessively, collagen synthesis and degradation become unbalanced, and transforming growth factor-β1 (TGF-β1) signaling is continuously activated, normal, orderly collagen fiber regeneration is replaced by disordered, proliferating collagen, resulting in hypertrophic scars. hypertrophic scar Existing research indicates that maintaining a moist wound microenvironment, regulating fibroblast activity, and inhibiting excessive deposition of type I collagen with directional alignment are key strategies for preventing and mitigating scar formation.

[0004] Currently available products for improving pigmentation mostly rely on the inhibition of tyrosinase by a single whitening active ingredient (such as niacinamide, arbutin, vitamin C derivatives, kojic acid, etc.), with insufficient attention paid to the barrier damage and abnormal dermal microenvironment accompanying post-inflammatory hyperpigmentation. On the other hand, scar repair products mostly use silicone gel as a single functional component, relying on physical film-forming hydration to soften scar tissue, but they lack bioactive ingredients that promote the regeneration of normal tissue, resulting in slow onset and limited efficacy.

[0005] Existing literature reports the use of recombinant collagen in skin repair products. Recombinant collagen, especially recombinant human type III collagen, has biological activities such as promoting the migration of keratinocytes and fibroblasts, regulating extracellular matrix remodeling, and providing a microenvironment conducive to the orderly regeneration of tissues. However, recombinant collagen faces the following technical challenges in formulation: (1) it is sensitive to temperature, pH, and shear force, and conventional formulation processes can easily lead to its denaturation and inactivation; (2) when used alone, its transdermal efficiency is limited, making it difficult to maintain an effective concentration at the target site; (3) in systems containing organosilicon, the compatibility between the organosilicon phase and the aqueous phase needs to be addressed to achieve uniform and stable dispersion.

[0006] Chinese patent application CN115804864B discloses a synergistic repair-promoting, heat-stable recombinant type III humanized collagen gel and its preparation method, but its formulation does not contain a silicone elastomer mixture, thus failing to provide the same sealing barrier function as silicone gels. Chinese patent application CN107157986B discloses a silicone gel with concealing and scar-treating properties and its preparation method, but it relies solely on the physical effects of silicone and does not contain bioactive recombinant collagen. The two differ fundamentally in their technical pathways and mechanisms of action. Summary of the Invention

[0007] In view of this, the present invention proposes a recombinant collagen composition and its preparation method that have the effect of improving pigmentation and reducing scar formation, thereby solving the above problems.

[0008] The technical solution of the present invention is achieved as follows: a recombinant collagen composition having the effect of improving pigmentation and reducing scar formation, comprising the following components in weight percentage: 1%~10% organosilicon, 0.1%~5% recombinant collagen, 3%~15% glycerol, 0.1%~1.5% carbomer, 0.2%~2% 1,2-hexanediol, 0.1%~1% p-hydroxyacetophenone, 0.05%~1% polyoxyethylene hydrogenated castor oil, and water, wherein the pH value of the composition is 5.5~7.0; The organosilicon is a mixture composed of polydimethylsiloxane, cyclopentadimethylsiloxane, fumed silica, and a polydimethylsiloxane crosslinked polymer, wherein the weight ratio of polydimethylsiloxane, cyclopentadimethylsiloxane, fumed silica, and the polydimethylsiloxane crosslinked polymer is 1:(0.3~0.8):(0.05~0.3):(0.1~0.5).

[0009] Furthermore, the recombinant collagen is at least one of recombinant human type III collagen, recombinant human type I collagen, or recombinant human-like collagen, with a molecular weight of 30-120 kDa.

[0010] Furthermore, in the organosilicon mixture, the specific surface area of ​​fumed silica is 150~380 m². 2 / g, with a native particle size of 7~40nm; the polydimethylsiloxane crosslinked polymer is a polydimethylsiloxane / vinyl polydimethylsiloxane crosslinked polymer, wherein the polydimethylsiloxane / vinyl polydimethylsiloxane crosslinked polymer.

[0011] Furthermore, the carbomer is carbomer 940 or carbomer 980.

[0012] Furthermore, the composition also comprises sodium hyaluronate and / or nicotinamide, wherein the content of sodium hyaluronate is 0.01% to 0.5% and the content of nicotinamide is 0.1% to 1% by weight.

[0013] Furthermore, the molecular weight of the sodium hyaluronate is 800kDa~1800kDa.

[0014] The preparation method of the above-mentioned recombinant collagen composition includes the following steps: S1. Disperse carbomer evenly in water that accounts for 60-80% of the total water mass, and let it stand to fully swell to obtain phase A; S2. Mix glycerol, 1,2-hexanediol and p-hydroxyacetophenone and heat to 50-70°C, stirring until completely dissolved to obtain phase B; S3. Slowly add phase B to phase A while stirring, homogenize for 1-5 minutes, adjust pH to 5.5-7.0, and obtain the gel matrix; S4. Dissolve the recombinant collagen in the remaining water and slowly add it to the gel matrix obtained in step S3 at 25~35℃ under light-protected conditions, stirring and mixing evenly. S5. After pre-mixing the organosilicon mixture with the polyoxyethylene hydrogenated castor oil evenly, add it to the mixture obtained in step S4 under stirring, stir evenly, and degas to obtain the final product.

[0015] Furthermore, the homogenization speed in step S3 is 3000~8000 rpm; the addition rate of the recombinant collagen solution in step S4 is 0.5~5 mL / min, and the stirring speed is 50~200 rpm.

[0016] Further, the organosilicon mixture in step S5 is prepared in advance by the following method: after mixing polydimethylsiloxane and cyclopentadimethylsiloxane evenly, fumed silica and polydimethylsiloxane crosslinking polymer are added sequentially under stirring, and homogenized at 5000~12000 rpm for 3~10 minutes to form a homogeneous organosilicon elastomer mixture.

[0017] The above-mentioned recombinant collagen composition is used in the preparation of topical skin formulations for improving post-inflammatory hyperpigmentation and inhibiting the formation of hypertrophic scars. Preferably, the topical skin formulation includes any one of scar repair gel, post-cosmetic surgery repair dressing, acne scar repair essence, and wound care gel.

[0018] Compared with the prior art, the beneficial effects of the present invention are: This invention combines an organosilicon complex with recombinant collagen to construct a physical barrier and biological repair system. The organosilicon forms a breathable protective film on the skin surface, softening scars and inhibiting excessive fibroblast proliferation and abnormal collagen deposition through occlusive hydration. Simultaneously, it isolates external stimuli to reduce inflammation and decrease inflammation-mediated melanin secretion. The recombinant collagen promotes epidermal cell proliferation and migration, accelerates skin barrier repair, and downregulates tyrosinase activity to reduce melanin deposition. After combination, the occlusive microenvironment of the organosilicon prolongs the skin retention time of the recombinant collagen, which in turn accelerates epidermal healing and shortens the pigmentation window. The complementary and synergistic mechanisms of action result in a superior effect in improving pigmentation and inhibiting scar formation compared to the simple superposition of single components.

[0019] This invention employs a four-component compounded organic silicone system with a specific ratio. Polydimethylsiloxane provides long-lasting film-forming and water-locking effects, cyclopentadimethylsiloxane enhances spreadability and reduces stickiness, fumed silica regulates the thixotropy of the system, and the polydimethylsiloxane crosslinked polymer enhances the dispersion stability of the silicone phase in the hydrogel matrix. The four components work synergistically to ensure the film-forming effect of scar repair while solving the problems of stickiness and poor compatibility with water phase in traditional silicone preparations.

[0020] This invention uses carbomer hydrogel as a matrix, combined with a polyoxyethylene hydrogenated castor oil emulsification system and an organosilicon premixing homogenization process, to uniformly disperse the silicon phase in the gel matrix. No stratification or water separation occurs after 3 months of storage at room temperature, demonstrating excellent system stability. During preparation, recombinant collagen is loaded using a low-temperature, light-protected, and low-speed feeding method to avoid protein denaturation caused by high temperature and strong shear, significantly improving the activity retention rate of the product during its shelf life.

[0021] This invention employs a mild preservative system composed of 1,2-hexanediol and p-hydroxyacetophenone. The pH value of the system is suitable for the weakly acidic environment of the skin, and it has low irritation to damaged and sensitive skin. It can be widely used in acne scar repair, trauma and postoperative hypertrophic scar care, and medical aesthetic repair, and has both preventive and improving effects. Detailed Implementation

[0022] To better understand the technical content of this invention, specific embodiments are provided below to further illustrate the invention.

[0023] Unless otherwise specified, the experimental methods used in the embodiments of this invention are all conventional methods.

[0024] Unless otherwise specified, all materials and reagents used in the embodiments of this invention are commercially available.

[0025] Examples 1-5: Preparation of the basic composition The compositions of Examples 1-5 were prepared according to the weight percentage composition shown in Table 1 using the following general preparation method.

[0026] Table 1. Composition (wt%) of Examples 1-5

[0027] The composition (wt%) of the organosilicon mixtures in each embodiment is shown in Table 2 below:

[0028] The specific surface area of ​​the fumed silica used is 200 m². 2 / g, native particle size 12±1nm.

[0029] Preparation method: 1. Pre-preparation of organosilicon mixture: Weigh polydimethylsiloxane and cyclopentadimethylsiloxane according to the ratio, and stir to mix evenly; add fumed silica and polydimethylsiloxane / vinyl polydimethylsiloxane crosslinked polymer in sequence under low speed stirring. After the addition is completed, homogenize at 8000 rpm for 5 minutes to obtain a homogeneous organosilicon elastomer mixture for later use.

[0030] 2. Preparation of Phase A: Disperse the prescribed amount of carbomer evenly in purified water that accounts for 70% of the total mass of purified water, avoiding clumping, and let it stand at room temperature (25°C) for 2 hours until it is fully swollen to obtain a uniform and transparent Phase A.

[0031] 3. Preparation of phase B: Weigh glycerol, 1,2-hexanediol and p-hydroxyacetophenone according to the ratio, mix them and heat in a water bath to 60°C, and stir at 200 rpm until completely dissolved to obtain a transparent and clear phase B.

[0032] 4. Gel matrix preparation: Phase B was slowly added to Phase A under stirring at 300 rpm. After the addition was completed, the mixture was homogenized at 5000 rpm for 2 minutes. Then, 10 wt% sodium hydroxide aqueous solution was added to adjust the pH of the system to 6.0 ± 0.2 to obtain a uniform and transparent gel matrix.

[0033] 5. Loading of active components: Dissolve recombinant collagen in the remaining purified water and slowly add it dropwise to the gel matrix at a rate of 2 mL / min under light-protected conditions, stirring at a low speed of 100 rpm until homogeneous.

[0034] 6. Silicon phase dispersion: The pre-prepared organosilicon mixture is mixed evenly with polyoxyethylene hydrogenated castor oil, and then added to the mixing system of step 5 above under stirring. After stirring evenly, the mixture is degassed under vacuum of -0.08MPa for 15 minutes until no bubbles are present, thus obtaining the recombinant collagen gel composition.

[0035] To verify the synergistic effect and formulation advantages of the present invention, the following comparative examples were set up: Comparative Example 1 Without adding organosilicon mixtures, the remaining components and preparation methods are the same as in Example 1.

[0036] Comparative Example 2 No recombinant collagen was added; the remaining components and preparation method were the same as in Example 1.

[0037] Comparative Example 3 The ratio of organosilicon is not within the limits of this invention. The weight ratio of polydimethylsiloxane, cyclopentadimethylsiloxane, fumed silica, and crosslinked polymer is 1:0.1:0.5:0.05. The total amount of organosilicon added is the same as in Example 1. The other components and preparation methods are the same as in Example 1.

[0038] Comparative Example 4 The preparation method is different. In step 5, the recombinant collagen is added to the aqueous phase at 75°C. The rest is the same as in Example 1.

[0039] Effect verification test Experimental Example 1: System Stability Test The samples from Examples 1-5 and Comparative Example 3 were placed under ambient temperature (25℃), high temperature (40℃), and low temperature cycling (-10℃~25℃ alternating) conditions for 3 months, and their appearance was observed. The results are shown in Table 3.

[0040]

[0041] The results show that the quaternary organosilicon composite with the specified ratio of the present invention can significantly improve the storage stability of the composition under high and low temperature conditions and avoid the separation of the organosilicon phase and the hydrogel matrix; the stability of the comparative example 3, which deviates from the ratio, is significantly reduced.

[0042] Experimental Example 2: In vitro efficacy verification Cell models were used to verify the pigmentation improvement and scar inhibition effects of the samples: 1. Tyrosinase inhibition rate 1.1 Experimental Materials and Reagents B16 mouse melanocyte cell line; DMEM high-glucose complete medium (containing 10% fetal bovine serum and 1% penicillin-streptomycin); 0.25% trypsin-EDTA digestion solution; L-DOPA; Triton X-100 lysis buffer; PBS buffer (pH 6.8); BCA protein quantification kit; 6-well cell culture plate; microplate reader; high-speed refrigerated centrifuge; CO2 incubator.

[0043] 1.2 Test Methods (1) Cell seeding: B16 melanocytes in the logarithmic growth phase were taken, digested with 0.25% trypsin to prepare a cell suspension, and the cell density was adjusted to 2×10⁻⁶. 5 Cells were seeded at a density of 1 / mL into 6-well culture plates, with 2 mL of cell suspension added to each well. The plates were then incubated at 37°C, 5% CO2, and saturated humidity for 24 hours until the cells adhered to the plate and reached 70%–80% confluence.

[0044] (2) Drug administration: Discard the original culture medium in the wells, replace the drug administration group with complete culture medium containing 10% (v / v) of the test sample, and replace the blank control group with complete culture medium containing an equal volume of PBS; set up 3 replicates for each group, and put them back into the incubator to continue incubation for 48h.

[0045] (3) Cell lysis and protein quantification: Discard the culture medium and wash the cells twice with pre-cooled PBS; add 100 μL of 1% Triton X-100 lysis buffer (containing 0.1 mM PMSF protease inhibitor) to each well, place on ice for 30 min for lysis, and collect the cell lysis buffer after repeated pipetting; centrifuge at 4℃ and 12000 rpm for 15 min and take the supernatant; determine the total protein concentration of the supernatant of each group using the BCA method, and adjust all samples to the same protein concentration with lysis buffer.

[0046] (4) Enzyme activity assay: Take a 96-well plate, add 80 μL of crude enzyme solution with adjusted concentration to each well, and then add 20 μL of 0.1% L-DOPA solution (prepared with pH 6.8 PBS); mix gently and incubate in a 37℃ water bath in the dark for 60 min. Immediately measure the absorbance (OD) of each well at a wavelength of 475 nm using a microplate reader. 475 ) 1.3 Result Calculation The relative activity and inhibition rate of tyrosinase are calculated using the following formula: Relative activity of tyrosinase (%) = ×100% Tyrosinase inhibition rate (%) = (1 - relative tyrosinase activity) × 100% 2. Fibroblast proliferation inhibition rate: 2.1 Experimental Materials and Reagents Human skin fibroblasts (HSF); DMEM low-glucose complete medium; fetal bovine serum; recombinant human transforming growth factor-β1 (TGF-β1); CCK-8 cell proliferation assay kit; 96-well cell culture plate; microplate reader; CO2 incubator.

[0047] 2.2 Test Methods Human skin fibroblasts in the logarithmic growth phase were collected, digested with trypsin, and a single-cell suspension was prepared. The cell density was adjusted to 5 × 10⁻⁶ cells / year. 4Cells were seeded at a density of 100 μL / mL into 96-well cell culture plates (approximately 5000 cells per well); the plates were then incubated at 37°C with 5% CO2 for 24 hours until the cells were fully adherent. The original culture medium was discarded, and the cells were treated according to the following groups, with 6 replicates per group: (1) Normal control group: 100 μL of complete culture medium was added; (2) Model control group: 100 μL of complete culture medium containing 10 ng / mL TGF-β1 was added; (3) Drug administration group: Add 100 μL of complete culture medium containing 10 ng / mL TGF-β1 and 10% (v / v) of the test composition.

[0048] After sample addition, return the 96-well plate to the incubator and continue incubation for 48 hours. After incubation, slowly add 10 μL of LCK-8 reagent to each well, avoiding the formation of air bubbles; gently vortex to mix, then incubate in the dark for 2 hours; measure the absorbance (OD) of each well at 450 nm using a microplate reader. 450 At the same time, blank zeroing wells containing only culture medium and CCK-8 reagent are set up, and the final value is reduced by the OD value of the blank wells.

[0049] 2.3 Result Calculation Using a TGF-β1-induced abnormal fibroblast proliferation model as a benchmark, the inhibition rate of the composition on abnormal fibroblast proliferation was calculated using the following formula: Fibroblast proliferation inhibition rate (%) = ×100% 3. Collagen activity retention rate: 3.1 Reagents and Materials Recombinant human type III collagen ELISA quantitative detection kit, microplate reader, constant temperature incubator, micropipette, sample diluent.

[0050] 3.2 Operating Procedures (1) Sample preparation: Take fresh samples on the day of preparation (day 0) and aged samples after being sealed at 40℃ for 1 month; use the sample diluent provided with the kit to dilute the samples in a gradient according to the preset ratio so that the detection values ​​fall within the linear range of the standard curve.

[0051] (2) Preparation of standard: According to the kit instructions, the recombinant type III collagen standard is serially diluted with diluent to prepare standard solutions with 6 to 8 gradient concentrations.

[0052] (3) Adding and incubating: Add 100 μL of standard solution and 100 μL of sample solution to the enzyme-labeled plate, seal the plate with the sealing film, and incubate in a 37°C incubator for 90 min. After incubation, shake off the liquid in the wells and do not wash.

[0053] (4) Antibody-enzyme binding: Add 100 μL of biotin-labeled anti-type III collagen primary antibody working solution to each well and incubate at 37°C for 60 min; discard the liquid, wash the plate 3 times with washing buffer, soaking for 1 min each time, and pat dry. Add 100 μL of horseradish peroxidase-labeled secondary antibody working solution to each well and incubate at 37°C in the dark for 30 min; discard the liquid, wash the plate 5 times, and pat dry.

[0054] (5) Color development and reading: Add 90 μL of substrate color development solution to each well and develop color at 37℃ in the dark for 15 min; add 50 μL of stop solution to each well, mix gently to stop the reaction, and measure the OD value of each well at 450 nm wavelength using an ELISA reader within 10 min.

[0055] (6) Concentration calculation: A standard curve is prepared with the standard concentration as the abscissa and the corresponding OD value as the ordinate. The OD values ​​of each sample are substituted to calculate the active concentration of recombinant collagen in the sample.

[0056] 3.3 Calculation Formula Collagen activity retention rate (%) = Collagen activity concentration of the sample after storage / Collagen activity concentration of the initial sample × 100% The test results are shown in Table 4.

[0057] Table 4 Results of in vitro efficacy tests

[0058] Results analysis: The tyrosinase inhibition rate and fibroblast proliferation inhibition rate of Example 1 were significantly higher than those of Comparative Example 1 and Comparative Example 2, demonstrating that the combination of organosilicon and recombinant collagen has a clear synergistic effect, rather than a simple superposition of the effects of a single component.

[0059] Comparative Example 3 showed decreased film-forming properties and dispersibility due to the deviation of the organosilicon ratio from the optimal range, with both effects being lower than those of Example 1. This demonstrates that the quaternary organosilicon ratio specified in this invention is the key to achieving excellent performance.

[0060] Comparative Example 4 showed that high-temperature feeding caused collagen denaturation and inactivation, resulting in a significant decrease in protein activity retention and efficacy. This demonstrates that the low-temperature preparation process of this invention is crucial for ensuring product efficacy.

[0061] Test Example 3: Skin Irritation Test The acute skin irritation test method for rabbits was used. The samples from Examples 1-3 were applied to intact and damaged skin of rabbits and observed continuously for 72 hours. The scores of erythema and edema were recorded.

[0062] The results showed that the irritation scores for both intact and damaged skin were 0, with no irritation reactions such as erythema or edema, proving that the composition of the present invention is mild and non-irritating, and suitable for damaged skin and skin after medical aesthetic procedures.

[0063] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A recombinant collagen composition with the effects of improving pigmentation and reducing scar formation, characterized in that, The composition comprises the following components in weight percentage: 1%–10% organosilicon, 0.1%–5% recombinant collagen, 3%–15% glycerol, 0.1%–1.5% carbomer, 0.2%–2% 1,2-hexanediol, 0.1%–1% p-hydroxyacetophenone, 0.05%–1% polyoxyethylene hydrogenated castor oil, and water, wherein the pH of the composition is 5.5–7.0; The organosilicon is a mixture composed of polydimethylsiloxane, cyclopentadimethylsiloxane, fumed silica, and a polydimethylsiloxane crosslinked polymer, wherein the weight ratio of polydimethylsiloxane, cyclopentadimethylsiloxane, fumed silica, and the polydimethylsiloxane crosslinked polymer is 1:(0.3~0.8):(0.05~0.3):(0.1~0.5).

2. The recombinant collagen composition according to claim 1, characterized in that, The recombinant collagen is at least one of recombinant human type III collagen, recombinant human type I collagen, or recombinant human-like collagen, with a molecular weight of 30-120 kDa.

3. The recombinant collagen composition according to claim 1, characterized in that, In the organosilicon mixture, the specific surface area of ​​fumed silica is 150~380 m². 2 / g, with a native particle size of 7~40nm; the polydimethylsiloxane crosslinked polymer is a polydimethylsiloxane / vinyl polydimethylsiloxane crosslinked polymer.

4. The recombinant collagen composition according to claim 1, characterized in that, The carbomer is either carbomer 940 or carbomer 980.

5. The recombinant collagen composition according to claim 1, characterized in that, The composition further comprises sodium hyaluronate and / or nicotinamide, wherein the content of sodium hyaluronate is 0.01% to 0.5% and the content of nicotinamide is 0.1% to 1% by weight.

6. The recombinant collagen composition according to claim 5, characterized in that, The molecular weight of the sodium hyaluronate is 800kDa~1800kDa.

7. The method for preparing the recombinant collagen composition according to any one of claims 1 to 6, characterized in that, Includes the following steps: S1. Disperse carbomer evenly in water that accounts for 60-80% of the total water mass, and let it stand to fully swell to obtain phase A; S2. Mix glycerol, 1,2-hexanediol and p-hydroxyacetophenone and heat to 50-70°C, stirring until completely dissolved to obtain phase B; S3. Slowly add phase B to phase A while stirring, homogenize for 1-5 minutes, adjust pH to 5.5-7.0, and obtain the gel matrix; S4. Dissolve the recombinant collagen in the remaining water and slowly add it to the gel matrix obtained in step S3 at 25~35℃ under light-protected conditions, stirring and mixing evenly. S5. After pre-mixing the organosilicon mixture with the polyoxyethylene hydrogenated castor oil evenly, add it to the mixture obtained in step S4 under stirring, stir evenly, and degas to obtain the final product.

8. The preparation method according to claim 7, characterized in that, The homogenization speed in step S3 is 3000~8000 rpm; the addition rate of the recombinant collagen solution in step S4 is 0.5~5 mL / min, and the stirring speed is 50~200 rpm.

9. The preparation method according to claim 7, characterized in that, The organosilicon mixture in step S5 is prepared in advance by the following method: after mixing polydimethylsiloxane and cyclopentadimethylsiloxane evenly, fumed silica and polydimethylsiloxane crosslinking polymer are added sequentially under stirring, and homogenized at 5000~12000 rpm for 3~10 minutes to form a homogeneous organosilicon elastomer mixture.

10. The use of the recombinant collagen composition according to any one of claims 1 to 6 in the preparation of a topical skin formulation for improving post-inflammatory hyperpigmentation and inhibiting the formation of hypertrophic scars.

Images